NCT03560531 is a Phase 1/2, open-label, multicenter, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ZN-c5 administered orally in subjects with advanced ER+ HER2- BC [90]. The gene discussed is ESR1; the disease is breast cancer.